Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.6048
Abstract: 6048 Background: Recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) represents a marked unmet need. ROR2 is a cell-surface transmembrane receptor protein tyrosine kinase highly expressed in several tumor types… read more here.
Keywords: phase trial; ozuriftamab vedotin; vedotin; binding ror2 ... See more keywords